Public Health

Pediatric safety and pharmacokinetic findings supported expanding leniolisib to children aged 4 to 11 years who weigh at least 27 kg, establishing the first FDA-approved treatment for activated...

A multisite surveillance study published in Pediatrics assessed trends and determinants of influenza antiviral use in hospitalized children across the United States before and during the late COVID-19...

Results from the SOHO-01 trial supported expanded use of sevabertinib in adults with HER2-mutated, locally advanced or metastatic nonsquamous non–small cell lung cancer, including patients who had not...

CDC retained prior influenza vaccine recommendations for 2026–2027 and detailed vaccine selection, timing, dosing, and precautions.

In an emulated trial of 56,652 matched pairs with COPD, vaccination was associated with a 39% lower hazard of hospitalized influenza.

A systematic review of 155 studies found COVID-19 vaccines reduced severe outcomes across age and risk groups without new safety signals.

A prespecified DAN-RSV trial analysis found RSVpreF reduced RSV-related hospitalization regardless of heart failure status.

AI chatbot engagement was associated with greater PrEP initiation, retention, and appointment attendance in a retrospective US cohort.

An updated evidence-based practice guideline published in Headache outlines when to initiate pharmacologic migraine prevention in adults and how to select, assess, and discontinue treatment.

The FDA approval addresses acquired endocrine resistance by allowing eligible patients with HR-positive, HER2-negative advanced breast cancer to switch to camizestrant when an ESR1 mutation is detected in...